12-Epi-Salvinorin B | 1232837-61-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 12-Epi-Salvinorin B
• 英文别名: 12-epi-salvB；methyl (2R,4aR,6aR,7R,9S,10aS,10bR)-2-(furan-3-yl)-9-hydroxy-6a,10b-dimethyl-4,10-dioxo-2,4a,5,6,7,8,9,10a-octahydro-1H-benzo[f]isochromene-7-carboxylate
• CAS: 1232837-61-4
• 化学式: C₂₁H₂₆O₇
• 分子量: 390.433
• InChiKey: BLTMVAIOAAGYAR-ZNKMMSAYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  103
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  12-Epi-Salvinorin B 、 氯甲基乙醚 在 N,N-二异丙基乙胺 、 sodium iodide 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 18.0h， 以65%的产率得到EtOMe-12-Epi-Salvinorin B
  参考文献：
  名称：

  [EN] SALVINORIN DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE SALVINORINE ET LEURS UTILISATIONS

  摘要：

  该发明涉及选择性作用于κ阿片受体的salvinorin组合物；利用选择性κ受体激动剂治疗躁狂症的方法；以及利用salvinorin组合物治疗情绪障碍，如抑郁障碍和躁狂障碍的方法。

  公开号：

  WO2010075045A1
• 作为产物：
  描述：

  12-epi-Salvinorin A 在 水 、 碳酸氢钠 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以58%的产率得到12-Epi-Salvinorin B
  参考文献：
  名称：

  [EN] SALVINORIN DERIVATIVES AND USES THEREOF
  [FR] DÉRIVÉS DE SALVINORINE ET LEURS UTILISATIONS

  摘要：

  该发明涉及选择性作用于κ阿片受体的salvinorin组合物；利用选择性κ受体激动剂治疗躁狂症的方法；以及利用salvinorin组合物治疗情绪障碍，如抑郁障碍和躁狂障碍的方法。

  公开号：

  WO2010075045A1

文献信息

• [EN] SALVINORIN DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SALVINORINE ET LEURS UTILISATIONS
  申请人：MCLEAN HOSPITAL CORP

  公开号：WO2010075045A1

  公开（公告）日：2010-07-01

  The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.

  该发明涉及选择性作用于κ阿片受体的salvinorin组合物；利用选择性κ受体激动剂治疗躁狂症的方法；以及利用salvinorin组合物治疗情绪障碍，如抑郁障碍和躁狂障碍的方法。
• SALVINORIN DERIVATIVES AND USES THEREOF
  申请人：Beguin Cecile

  公开号：US20120010219A1

  公开（公告）日：2012-01-12

  The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.

  该发明涉及选择性作用于kappa阿片受体的沙尔维诺林组合物；利用选择性kappa受体激动剂治疗躁狂症的方法；以及利用沙尔维诺林组合物治疗情感障碍，如抑郁症和躁郁症的方法。
• Salvinorin derivatives and uses thereof
  申请人：Beguin Cecile

  公开号：US08492564B2

  公开（公告）日：2013-07-23

  The invention features salvinorin compositions that are selective for kappa opioid receptors; methods of treating mania by using a selective kappa receptor agonist; and methods of treating mood disorders, such as depressive disorders and manic disorders, using salvinorin compositions.

  本发明涉及选择性针对kappa阿片受体的鼠曲草酮组合物；使用选择性kappa受体激动剂治疗躁狂症的方法；以及使用鼠曲草酮组合物治疗情绪障碍，如抑郁症和躁郁症的方法。
• COMBINATION PRODUCT FOR THE INDUCTION AND/OR MAINTENANCE OF GENERAL ANESTHESIA
  申请人：BLUMENTECH, S.L.

  公开号：US20210186927A1

  公开（公告）日：2021-06-24

  The state of general anesthesia (GA) is essential to many surgical and medical procedures. This state is characterized by loss of consciousness, deep analgesia and suppression of movements. GA is rarely achieved with a single drug, usually requiring the combination of various pharmacological agents. Each drug can interact with one or more molecular targets affecting neuronal excitability and synaptic transmission in multiple regions of the CNS. Agonists of the μ-opioid receptor are commonly used in GA to cause analgesia, but not to induce or maintain loss of consciousness or movement suppression. Additionally, agonists of the μ-opioid receptor can cause serious unwanted side effects, e.g. respiratory depression. The present invention provides alternative combination products based on K-opioid receptor agonists. These combination products unexpectedly induced loss of consciousness, and were able to achieve and maintain GA. Furthermore, the combination products suppressed pain perception without the need of a μ-opioid receptor agonist. The combination of Salvinorin A, a selective κ-opioid receptor agonist, with Diazepam or Medetomidine surprisingly led to rapid consciousness, deep analgesia and movement suppression. This combination was found to effectively induce and maintain a state of general anesthesia.
• US8492564B2
  申请人：——

  公开号：US8492564B2

  公开（公告）日：2013-07-23